Vyalev a continuous subcutaneousinfusion for Parkinson’s disease is now launched in Japan – AbbVie
AbbVie has launched Vyalev (foslevodopa + foscarbidopa), a continuous subcutaneous infusion for Parkinson’s disease, in Japan on July 26. This is the first Parkinson’s drug in the country… read more.
